22 Apr 2016 10:49
4D pharma plc
(the "Company" or "4D")
Annual Report and Notice of AGM
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, is pleased to announce that the Annual Report and Accounts for the year to 31 December 2015, incorporating the Notice of the Company's Annual General Meeting ("AGM"), has been posted to shareholders.
An electronic copy of the Annual Report and Accounts is available on the Company's website, www.4dpharmaplc.com.
The AGM will be held at 2 p.m. on 23 May 2016 at the Gridiron Building, 1 Pancras Square, London N1C 4AG.
For further information please contact:
4D | + 44 (0)113 895 0130 |
Laurie Dale, Company Secretary
|
|
|
|
Zeus Capital Limited - Nomad and Broker |
|
Dan Bate | +44 (0) 161 831 1512 |
Dominic Wilson | +44 (0) 203 829 5000 |
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 15 therapeutic programmes covering autoimmune diseases, CNS disorders and cancer; with two programmes in patient trials, and the expectation to initiate another three programmes over the coming twelve months.